<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SKYLA- levonorgestrel intrauterine device </strong><br>Bayer HealthCare Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SKYLA safely and effectively.  See full prescribing information for SKYLA.<br><br>SKYLA (levonorgestrel-releasing intrauterine system)<br>Initial U.S. Approval: 2000</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Skyla is a progestin-containing intrauterine system (IUS) indicated for prevention of pregnancy for up to 3 years. (<a href="#ID_1c4e9615-eb51-4433-8ff5-ce9e6c594861">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Release rate of levonorgestrel (LNG) is 14 mcg/day after 24 days and declines to 5 mcg/day after 3 years; Skyla must be removed or replaced after 3 years. (<a href="#ID_1c600e58-b519-4991-ae02-f61ccaa58ec3">2</a>)</dd>
<dt>•</dt>
<dd>To be inserted by a trained healthcare provider using strict aseptic technique. Follow insertion instructions exactly as described. (<a href="#ID_1c600e58-b519-4991-ae02-f61ccaa58ec3">2</a>) </dd>
<dt>•</dt>
<dd>Patient should be re-examined and evaluated 4 to 6 weeks after insertion; then, yearly or more often if indicated. (<a href="#ID_e2cb2ede-0982-408c-9996-83b1604dca42">2.2</a>)</dd>
</dl></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>One sterile intrauterine system consisting of a T-shaped polyethylene frame with a steroid reservoir containing 13.5 mg levonorgestrel packaged within a sterile inserter (3)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy or suspicion of pregnancy. Cannot be used for post-coital contraception (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd>Congenital or acquired uterine anomaly if it distorts the uterine cavity (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> (PID) or a history of PID unless there has been a subsequent intrauterine pregnancy (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd>Postpartum <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span> or infected abortion in the past 3 months (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd>Known or suspected uterine or cervical neoplasia (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd>Known or suspected breast cancer or other progestin-sensitive cancer (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine bleeding</span> of unknown etiology (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd>Untreated acute <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span> or <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> or other lower genital tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd>Acute liver disease or <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span> (benign or malignant) (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd>Increased susceptibility to <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infection</span> (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd>A previous intrauterine device (IUD) that has not been removed (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of Skyla (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Remove Skyla if pregnancy occurs with Skyla in place. There is increased risk of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> including loss of fertility, pregnancy loss, septic abortion (including <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), and <span class="product-label-link" type="condition" conceptid="4273560" conceptname="Premature labor">premature labor</span> and delivery. (<a href="#ID_98be43d8-eb74-4bd7-992e-4c4fe58a1fc7">5.1</a>, <a href="#ID_f19ba4a2-53a7-4218-a9e4-88640f02eaa8">5.2</a>)</dd>
<dt>•</dt>
<dd>Group A <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infection</span> has been reported; strict aseptic technique is essential during insertion. (<a href="#ID_11851180-e0f7-4110-87a9-4a76a329d97d">5.3</a>)</dd>
<dt>•</dt>
<dd>Before using Skyla, consider the risks of PID. (<a href="#ID_23d1017a-874f-45d9-be1b-61c40e078409">5.4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> patterns become altered, may remain irregular and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> may ensue. (<a href="#ID_0db1bb63-88b7-4276-a016-9a56b73806a9">5.5</a>)</dd>
<dt>•</dt>
<dd>Perforation may occur and may reduce contraceptive effectiveness. Risk is increased if inserted in lactating women and may be increased if inserted in women with fixed retroverted uteri and postpartum. (<a href="#ID_6fd0d21d-a70b-451d-81f3-643de5b7427d">5.6</a>)</dd>
<dt>•</dt>
<dd>Partial or complete expulsion may occur. (<a href="#ID_918495c6-212c-432d-ae8b-8bd685d1f80b">5.7</a>)</dd>
<dt>•</dt>
<dd>Evaluate persistent enlarged ovarian follicles. (<a href="#ID_7b8a0cbf-cc78-42c4-b92d-5bd527d02e1a">5.8</a>)</dd>
<dt>•</dt>
<dd>Skyla can be safely scanned with MRI only under certain conditions (<a href="#ID_ab74cced-5f36-4d01-bf33-26311ecfc033">5.11</a>)</dd>
</dl></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions reported (&gt;10% users) are <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> pattern alterations, <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span>, abdominal/<span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>/<span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cyst</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (6) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or </span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Drugs or herbal products that induce certain enzymes, such as CYP3A4, may decrease the serum concentration of progestins. (<a href="#ID_efbaca52-20f3-4ef7-9053-d29b8bd8ca86">7</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Small amounts of progestins pass into breast milk resulting in detectable steroid levels in infant serum. (<a href="#ID_a22f3207-ca80-40ba-b9e1-f1e3c8a3242d">8.3)</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1. Insertion Instructions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patient Follow-up</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Removal of Skyla</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Continuation of Contraception after Removal </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic Pregnancy</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Intrauterine Pregnancy </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">Pelvic Infection</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Pattern Alterations</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Perforation</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Expulsion</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian Cysts</span> </a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Breast Cancer </a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Clinical Considerations for Use and Removal</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Magnetic Resonance Imaging (MRI) Information</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h2><a href="#section-9.1" class="toc">11.1 Skyla</a></h2>
<h2><a href="#section-9.2" class="toc">11.2 Inserter </a></h2>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1 Clinical Trials on Contraception</a></h2>
<h1><a href="#section-13" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc"> 17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_1c4e9615-eb51-4433-8ff5-ce9e6c594861"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Skyla<span class="Sup">®</span> is indicated to prevent pregnancy for up to 3 years. </p>
<p>The system should be replaced after 3 years if continued use is desired.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_1c600e58-b519-4991-ae02-f61ccaa58ec3"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Skyla contains 13.5 mg of levonorgestrel (LNG) released<span class="Italics"> in vivo</span> at a rate of approximately 14 mcg/day after 24 days. This rate decreases progressively to 5 mcg/day after 3 years. The average <span class="Italics">in vivo</span> release rate of LNG is approximately 6 mcg/day over a period of 3 years. </p>
<p>Skyla must be removed by the end of the third year and can be replaced at the time of removal with a new Skyla if continued contraceptive protection is desired. </p>
<p>Skyla is supplied within an inserter in a sterile package (see Figure 1) that must not be opened until required for insertion <span class="Italics">[see Description (<a href="#ID_e6ef8532-f26b-4a4a-91fb-2904d6f94a74">11</a>)]</span>. Do not use if the seal of the sterile package is broken or appears compromised. Use strict aseptic techniques throughout the insertion procedure <span class="Italics">[see Warnings and Precautions (<a href="#ID_11851180-e0f7-4110-87a9-4a76a329d97d">5.3</a>)]</span>.</p>
<div class="Figure">
<a name="id-1761753838"></a><img alt="Skyla Inserter" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=image-01.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_61ba293d-0026-4d69-9208-804ad04c71ae"></a><a name="section-2.1"></a><p></p>
<h2>2.1. Insertion Instructions</h2>
<dl>
<dt>•</dt>
<dd>A complete medical and social history should be obtained to determine conditions that might influence the selection of a levonorgestrel-releasing intrauterine system (LNG IUS) for contraception<span class="Italics">.</span> If indicated, perform a physical examination, and appropriate tests for any forms of genital or other sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. <span class="Italics">[See Contraindications (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>) and Warnings and Precautions (<a href="#ID_99e9b4b9-dc8f-47cf-b086-be5334b37eed">5.10</a>).]</span>
</dd>
<dt>•</dt>
<dd>Follow the insertion instructions exactly as described in order to ensure proper placement and avoid premature release of Skyla from the inserter. <span class="Underline">Once released, Skyla cannot be re-loaded</span>.</dd>
<dt>•</dt>
<dd>Skyla should be inserted by a trained healthcare provider. Healthcare providers should become thoroughly familiar with the insertion instructions before attempting insertion of Skyla. </dd>
<dt>•</dt>
<dd>Insertion may be associated with some <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">vasovagal reactions</span> (for example, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>) or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in an epileptic patient, especially in patients with a predisposition to these conditions. Consider administering analgesics prior to insertion.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d3d3f15d-89c5-49c1-997e-5c6005e0a7c8"></a><a name="section-2.1.1"></a><p></p>
<h3><span class="Bold">Timing of Insertion</span></h3>
<dl>
<dt>•</dt>
<dd>Insert Skyla into the uterine cavity during the first seven days of the menstrual cycle or immediately after a first trimester abortion. Back up contraception is not needed when Skyla is inserted as directed. </dd>
<dt>•</dt>
<dd>Postpone postpartum insertion and insertions following second trimester abortions a minimum of six weeks or until the uterus is fully involuted. If involution is delayed, wait until involution is complete before insertion <span class="Italics">[see Warnings and Precautions (<a href="#ID_6fd0d21d-a70b-451d-81f3-643de5b7427d">5.6</a>, <a href="#ID_918495c6-212c-432d-ae8b-8bd685d1f80b">5.7</a>)].</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b84e1a8b-8aa7-4187-8db8-c6e62cb0d7c9"></a><a name="section-2.1.2"></a><p></p>
<h3><span class="Bold">Tools for Insertion</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7e3faaff-94e1-44b5-80ff-c52057940974"></a><a name="section-2.1.2.1"></a><p></p>
<h4><span class="Bold">Preparation</span></h4>
<dl>
<dt>•</dt>
<dd>Gloves</dd>
<dt>•</dt>
<dd>Speculum</dd>
<dt>•</dt>
<dd>Sterile uterine sound</dd>
<dt>•</dt>
<dd>Sterile tenaculum</dd>
<dt>•</dt>
<dd>Antiseptic solution, applicator</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4b8c717a-30bf-45f8-9171-ce5eecb73a55"></a><a name="section-2.1.2.2"></a><p></p>
<h4><span class="Bold">Procedure</span></h4>
<dl>
<dt>•</dt>
<dd>Sterile gloves</dd>
<dt>•</dt>
<dd>Skyla with inserter in sealed package</dd>
<dt>•</dt>
<dd>Instruments and anesthesia for paracervical block, if anticipated</dd>
<dt>•</dt>
<dd>Consider having an unopened backup Skyla available</dd>
<dt>•</dt>
<dd>Sterile, sharp curved scissors</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1dd38f79-3c00-4a22-9011-2f7670ecca09"></a><a name="section-2.1.3"></a><p></p>
<h3><span class="Bold">Preparation for insertion </span></h3>
<dl>
<dt>•</dt>
<dd>Exclude pregnancy and confirm that there are no other contraindications to the use of Skyla.</dd>
<dt>•</dt>
<dd>Ensure that the patient understands the contents of the Patient Information Booklet and obtain the signed patient informed consent located on the last page of the Patient Information Booklet. </dd>
<dt>•</dt>
<dd>With the patient comfortably in lithotomy position, do a bimanual exam to establish the size, shape and position of the uterus. </dd>
<dt>•</dt>
<dd>Gently insert a speculum to visualize the cervix. </dd>
<dt>•</dt>
<dd>Thoroughly cleanse the cervix and vagina with a suitable antiseptic solution.</dd>
<dt>•</dt>
<dd>Prepare to sound the uterine cavity. Grasp the upper lip of the cervix with a tenaculum forceps and gently apply traction to stabilize and align the cervical canal with the uterine cavity. Perform a paracervical block if needed. If the uterus is retroverted, it may be more appropriate to grasp the lower lip of the cervix. The tenaculum should remain in position and gentle traction on the cervix should be maintained throughout the insertion procedure.</dd>
<dt>•</dt>
<dd>Gently insert a uterine sound to check the patency of the cervix, measure the depth of the uterine cavity in centimeters, confirm cavity direction, and detect the presence of any uterine anomaly. If you encounter difficulty or cervical stenosis, use dilatation, and not force, to overcome resistance. If cervical dilatation is required, consider using a paracervical block.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e429e166-d261-4acd-bfb0-95bb23e20f4a"></a><a name="section-2.1.4"></a><p></p>
<h3><span class="Bold">Insertion Procedure</span></h3>
<p class="First">Proceed with insertion only after completing the above steps and ascertaining that the patient is appropriate for Skyla. <span class="Underline">Ensure use of aseptic technique throughout the entire procedure</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e531643f-df08-466a-a4cd-ca7504989a91"></a><a name="section-2.1.4.1"></a><p></p>
<h4><span class="Bold">Step 1–Opening of the package</span></h4>
<dl>
<dt>•</dt>
<dd>Open the package (Figure 1). The contents of the package are sterile. </dd>
</dl>
<div class="Figure">
<a name="id106010848"></a><img alt="Opening the package" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-01.jpg"><p class="MultiMediaCaption">Figure 1: Opening the Skyla Package</p>
</div>
<dl>
<dt>•</dt>
<dd>Using sterile gloves, lift the handle of the sterile inserter and remove from the sterile package.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_11d8d060-0c15-4d4a-8c29-bcc633a939d1"></a><a name="section-2.1.4.2"></a><p></p>
<h4><span class="Bold">Step 2–Load Skyla into the insertion tube</span></h4>
<dl>
<dt>•</dt>
<dd>Push the slider <span class="Underline">forward </span>as far as possible in the direction of the arrow thereby moving the insertion tube over the Skyla T-body to load Skyla into the insertion tube (Figure 2). The tips of the arms will meet to form a rounded end that extends slightly beyond the insertion tube.</dd>
</dl>
<div class="Figure">
<a name="id2058351907"></a><img alt="Loading Skyla" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-02.jpg"><p class="MultiMediaCaption">Figure 2: Move slider all the way to the forward position to load Skyla</p>
</div>
<dl>
<dt>•</dt>
<dd>Maintain forward pressure with your thumb or forefinger on the slider<span class="Bold">. </span><span class="Underline">DO NOT move the slider downward at this time as this may prematurely release the threads of Skyla. Once the slider is moved below the mark, Skyla cannot be re-loaded</span><span class="Italics">.</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5abb738d-8641-41e5-8e7d-6830c1d2f013"></a><a name="section-2.1.4.3"></a><p></p>
<h4><span class="Bold">Step 3–Setting the Flange </span></h4>
<dl>
<dt>•</dt>
<dd>Holding the slider in this forward position, set the upper edge of the flange to correspond to the uterine depth (in centimeters) measured during sounding (Figure 3). </dd>
</dl>
<div class="Figure">
<a name="id-1840382444"></a><img alt="Setting Flange" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-03.jpg"><p class="MultiMediaCaption">Figure 3: Setting the flange</p>
</div>
<p class="First">Figure <a href="#_Ref">3</a>: Setting the flange</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8a8a3dba-666a-47dd-a69a-d585b5959d08"></a><a name="section-2.1.4.4"></a><p></p>
<h4><span class="Bold">Step 4–Skyla is now ready to be inserted</span></h4>
<dl>
<dt>•</dt>
<dd>Continue holding the slider in this forward position. Advance the inserter through the cervix until the flange is approximately 1.5–2 cm from the cervix and then pause (Figure 4). </dd>
</dl>
<div class="Figure">
<a name="id-726526913"></a><img alt="Advancing Tube" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-04.jpg"><p class="MultiMediaCaption">Figure 4: Advancing insertion tube until flange is 1.5 to 2 cm from the cervix  </p>
</div>
<p class="First"><span class="Underline">Do not force the inserter. If necessary, dilate the cervical canal.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6a0712e7-d880-4b94-8363-6e12b172c77b"></a><a name="section-2.1.4.5"></a><p></p>
<h4><span class="Bold">Step 5–Open the arms</span></h4>
<dl>
<dt>•</dt>
<dd>While holding the inserter steady, <span class="Underline">move the slider down to the mark</span> to release the arms of Skyla (Figure 5). Wait 10 seconds for the horizontal arms to open completely.</dd>
</dl>
<div class="Figure">
<a name="id40570478"></a><img alt="Releasing Arms" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-05.jpg"><p class="MultiMediaCaption">Figure 5: Move the slider back to the mark to release and open the arms</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_881a484a-6838-475b-a7d2-d693fd652d97"></a><a name="section-2.1.4.6"></a><p></p>
<h4><span class="Bold">Step 6–Advance to fundal position</span></h4>
<p class="First">Advance the inserter gently towards the fundus of the uterus <span class="Underline">until the flange touches the cervix</span>. If you encounter fundal resistance do not continue to advance. Skyla is now in the fundal position (Figure 6). <span class="Underline">Fundal positioning of Skyla is important to prevent expulsion</span>.</p>
<div class="Figure">
<a name="id-542060671"></a><img alt="Fundal Position" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-06.jpg"><p class="MultiMediaCaption">Figure 6: Move Skyla into the fundal position</p>
</div>
<p>Figure 6. Move Skyla into the fundal position</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6d586566-c528-4bed-baa8-0c35fc6f5416"></a><a name="section-2.1.4.7"></a><p></p>
<h4><span class="Bold">Step 7–Release Skyla and withdraw the inserter</span></h4>
<dl>
<dt>•</dt>
<dd>Holding the entire inserter firmly in place, release Skyla by moving <span class="Underline">the slider all the way down </span>(Figure 7).</dd>
</dl>
<div class="Figure">
<a name="id1965533472"></a><img alt="Skyla Figure 7 " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-07.jpg"><p class="MultiMediaCaption">Figure 7: Move the slider all the way down to release Skyla from the insertion tube</p>
</div>
<dl>
<dt>•</dt>
<dd>Continue to hold the slider all the way down while you slowly and gently withdraw the inserter from the uterus. </dd>
<dt>•</dt>
<dd>
<span class="Underline">Using a sharp, curved scissor, cut the threads</span> perpendicular, leaving about 3 cm visible outside of the cervix [cutting threads at an angle may leave sharp ends (Figure 8)]. Do not apply <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> or pull on the threads when cutting to prevent displacing Skyla. </dd>
</dl>
<p class="First">.</p>
<div class="Figure">
<a name="id-1676030697"></a><img alt="Cutting Threads" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-08.jpg"><p class="MultiMediaCaption">Figure 8: Cutting the threads</p>
</div>
<dl>
<dt> </dt>
<dd>Skyla insertion is now complete. Prescribe analgesics, if indicated. Keep a copy of the Consent Form with lot number for your records.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d6042b64-4515-4403-b533-2c770fb7cae7"></a><a name="section-2.1.5"></a><p></p>
<h3><span class="Bold">Important information to consider during or after insertion</span></h3>
<dl>
<dt>•</dt>
<dd>If you suspect that Skyla is not in the correct position, check placement (for example, using transvaginal ultrasound). Remove Skyla if it is not positioned completely within the uterus. A removed Skyla must not be re-inserted. </dd>
<dt>•</dt>
<dd>If there is clinical concern, exceptional <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during or after insertion, appropriate steps should be taken immediately to exclude perforation, such as physical examination and ultrasound.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e2cb2ede-0982-408c-9996-83b1604dca42"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patient Follow-up</h2>
<dl>
<dt>•</dt>
<dd>Patients should be reexamined and evaluated 4 to 6 weeks after insertion and once a year thereafter, or more frequently if clinically indicated.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0ebd607e-6c0c-45e5-a59a-c7023a674db6"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Removal of Skyla</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6f3544da-652d-48a7-ab75-325f8ed9c363"></a><a name="section-2.3.1"></a><p></p>
<h3><span class="Bold">Timing of Removal</span></h3>
<dl>
<dt>•</dt>
<dd>Skyla should not remain in the uterus after 3 years.</dd>
<dt>•</dt>
<dd>If pregnancy is not desired, the removal should be carried out during menstruation, provided the woman is still experiencing regular menses. If removal will occur at other times during the cycle, consider starting a new contraceptive method a week prior to removal. If removal occurs at other times during the cycle and the woman has had intercourse in the week prior to removal, she is at risk of pregnancy. <span class="Italics">[See Dosage and Administration (<a href="#ID_5107648b-46df-4d77-9106-0e477e19a379">2.4</a>).]</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_da546b25-75b2-4bca-a19c-107eba29ba79"></a><a name="section-2.3.2"></a><p></p>
<h3><span class="Bold">Tools for Removal</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_585c39d7-d0ef-476e-9a80-614e4503779f"></a><a name="section-2.3.2.1"></a><p></p>
<h4><span class="Bold">Preparation</span></h4>
<dl>
<dt>•</dt>
<dd>Gloves</dd>
<dt>•</dt>
<dd>Speculum</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_94e204b0-9e82-4ed8-83f4-8a61c3c015d9"></a><a name="section-2.3.2.2"></a><p></p>
<h4><span class="Bold">Procedure</span></h4>
<dl>
<dt>•</dt>
<dd>Sterile forceps</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bf7f83b2-9258-413f-b19d-507d44647b31"></a><a name="section-2.3.3"></a><p></p>
<h3><span class="Bold">Removal Procedure</span></h3>
<dl>
<dt>•</dt>
<dd>Remove Skyla by applying gentle traction on the threads with forceps (Figure 9). </dd>
</dl>
<div class="Figure">
<a name="id1040791428"></a><img alt="Remove Skyla" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-09.jpg"><p class="MultiMediaCaption">Figure 9: Removal of Skyla</p>
</div>
<dl>
<dt>•</dt>
<dd>If the threads are not visible, determine location of Skyla by ultrasound <span class="Italics">[see Warnings and Precautions (<a href="#ID_99e9b4b9-dc8f-47cf-b086-be5334b37eed">5.10</a>)]</span>.</dd>
<dt>•</dt>
<dd>If Skyla is found to be in the uterine cavity on ultrasound exam, it may be removed using a narrow forceps, such as an alligator forceps. This may require dilation of the cervical canal. After removal of Skyla, the system should be examined to ensure that it is intact. </dd>
<dt>•</dt>
<dd>Removal may be associated with some <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">vasovagal reactions</span> (for example, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in an epileptic patient).</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5107648b-46df-4d77-9106-0e477e19a379"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Continuation of Contraception after Removal </h2>
<dl>
<dt>•</dt>
<dd>If pregnancy is not desired and if a woman wishes to continue using Skyla, a new system can be inserted immediately after removal any time during the cycle.</dd>
<dt>•</dt>
<dd>If a patient with regular cycles wants to start a different birth control method, time removal and initiation of new method to ensure continuous contraception. Either remove Skyla during the first 7 days of the menstrual cycle and start the new method or start the new method at least 7 days prior to removing Skyla if removal is to occur at other times during the cycle.</dd>
<dt>•</dt>
<dd>If a patient with irregular cycles or <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> wants to start a different birth control method, start the new method at least 7 days before removal.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_21c13c1f-5e45-4dc6-8039-b4b4788ea317"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Skyla is a LNG-releasing IUS consisting of a T-shaped polyethylene frame with a steroid reservoir containing a total of 13.5 mg LNG. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS </h1>
<p class="First">The use of Skyla is contraindicated when one or more of the following conditions exist:</p>
<dl>
<dt>•</dt>
<dd>Pregnancy or suspicion of pregnancy; cannot be used for post-coital contraception </dd>
<dt>•</dt>
<dd>Congenital or acquired uterine anomaly including <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">fibroids</span> if they distort the uterine cavity </dd>
<dt>•</dt>
<dd>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> or a history of <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> unless there has been a subsequent intrauterine pregnancy</dd>
<dt>•</dt>
<dd>Postpartum <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span> or infected abortion in the past 3 months </dd>
<dt>•</dt>
<dd>Known or suspected uterine or cervical neoplasia </dd>
<dt>•</dt>
<dd>Known or suspected breast cancer or other progestin-sensitive cancer, now or in the past</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine bleeding</span> of unknown etiology </dd>
<dt>•</dt>
<dd>Untreated acute <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span> or <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, including <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> or other lower genital tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> until <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is controlled </dd>
<dt>•</dt>
<dd>Acute liver disease or <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span> (benign or malignant) </dd>
<dt>•</dt>
<dd>Conditions associated with increased susceptibility to <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infections</span></dd>
<dt>•</dt>
<dd>A previously inserted IUD that has not been removed</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_05baf8cd-12be-4970-b1dc-beb6704051d7"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_98be43d8-eb74-4bd7-992e-4c4fe58a1fc7"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic Pregnancy</span></h2>
<dl>
<dt> </dt>
<dd>Evaluate women for <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> if they become pregnant with Skyla in place because the likelihood of a pregnancy being ectopic is increased with Skyla. Approximately half of pregnancies that occur with Skyla in place are likely to be ectopic. Also consider the possibility of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> in the case of <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">lower abdominal pain</span>, especially in association with missed periods or if an amenorrheic woman starts <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </dd>
</dl>
<p class="First">The incidence of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> in clinical trials with Skyla, which excluded women with a history of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>, was approximately 0.1% per year. The risk of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> in women who have a history of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> and use Skyla is unknown. Women with a previous history of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>, tubal surgery or <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infection</span> carry a higher risk of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>. <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic pregnancy</span> may result in loss of fertility. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f19ba4a2-53a7-4218-a9e4-88640f02eaa8"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Intrauterine Pregnancy </h2>
<p class="First">If pregnancy occurs while using Skyla, remove Skyla because leaving it in place may increase the risk of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> and preterm labor. Removal of Skyla or probing of the uterus may also result in <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>. In the event of an intrauterine pregnancy with Skyla, consider the following:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e011b6b6-1a5a-42a1-83c9-46b63b4c8c76"></a><a name="section-5.2.1"></a><p></p>
<h3><span class="Bold">Septic abortion </span></h3>
<p class="First">In patients becoming pregnant with an IUD in place, septic abortion—with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, and death—may occur. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_001beefc-84c3-4fec-a009-c713fcb6dffc"></a><a name="section-5.2.2"></a><p></p>
<h3><span class="Bold">Continuation of pregnancy </span></h3>
<p class="First">If a woman becomes pregnant with Skyla in place and if Skyla cannot be removed or the woman chooses not to have it removed, warn her that failure to remove Skyla increases the risk of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4273560" conceptname="Premature labor">premature labor</span> and <span class="product-label-link" type="condition" conceptid="4086393" conceptname="Premature delivery">premature delivery</span>. Follow her pregnancy closely and advise her to report immediately any symptom that suggests complications of the pregnancy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9cb944bf-91ca-473f-ae98-4dac43da7b84"></a><a name="section-5.2.3"></a><p></p>
<h3><span class="Bold">Long-term effects and congenital anomalies</span></h3>
<p class="First">When pregnancy continues with Skyla in place, long-term effects on the offspring are unknown. With another LNG IUS, congenital anomalies in live births have occurred infrequently. No clear trend towards specific anomalies has been observed. Because of the local exposure of the fetus to LNG, the possibility of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> following exposure to Skyla cannot be completely excluded. Some observational data support a small increased risk of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">masculinization</span> of the external genitalia of the female fetus following exposure to progestins at doses greater than those currently used for oral contraception. Whether these data apply to Skyla is unknown. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_11851180-e0f7-4110-87a9-4a76a329d97d"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, including Group A streptococcal <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (GAS), have been reported following insertion of another LNG IUS. In some cases, severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> occurred within hours of insertion followed by <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> within days. Because <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from GAS is more likely if treatment is delayed, it is important to be aware of these rare but serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Aseptic technique during insertion of Skyla is essential in order to minimize serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as GAS. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_23d1017a-874f-45d9-be1b-61c40e078409"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">Pelvic Infection</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_73936415-389c-4fb9-8ee9-56643f772555"></a><a name="section-5.4.1"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">Pelvic Inflammatory Disease</span> (PID)</span></h3>
<p class="First">Skyla is contraindicated in the presence of known or suspected PID or in women with a history of PID unless there has been a subsequent intrauterine pregnancy <span class="Italics">[see Contraindications (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)]</span>. IUDs have been associated with an increased risk of PID, most likely due to organisms being introduced into the uterus during insertion.<span class="Sup">1  </span>In clinical trials, PID was observed in 0.4% of women overall and occurred more frequently within the first year and most often within the first month after insertion of Skyla. </p>
<p>Promptly examine users with complaints of lower abdominal or <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, odorous discharge, unexplained <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, genital lesions or sores. Remove Skyla in cases of recurrent <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span> or <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span>, or if an acute <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infection</span> is severe or does not respond to treatment. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_dcc3acd7-493d-46ae-b095-ced5520c1a8a"></a><a name="section-5.4.1.1"></a><p></p>
<h4><span class="Bold">Women at increased risk for PID </span></h4>
<p class="First">PID is often associated with a sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and Skyla does not protect against sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The risk of PID is greater for women who have multiple sexual partners, and also for women whose sexual partner(s) have multiple sexual partners. Women who have had PID are at increased risk for a recurrence or re-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. In particular, ascertain whether the woman is at increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (for example, <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immune deficiency syndrome</span> [AIDS], IV drug abuse).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_51b70fcb-d695-4efa-b4e6-d1864156c47e"></a><a name="section-5.4.1.2"></a><p></p>
<h4><span class="Bold">Asymptomatic PID </span></h4>
<p class="First">PID may be asymptomatic but still result in tubal damage and its sequelae.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_177feb5d-988d-493a-bb2a-c784b4d249c7"></a><a name="section-5.4.1.3"></a><p></p>
<h4><span class="Bold">Treatment of PID </span></h4>
<p class="First">Following a diagnosis of PID, or suspected PID, bacteriologic specimens should be obtained and antibiotic therapy should be initiated promptly. Removal of Skyla after initiation of antibiotic therapy is usually appropriate. Guidelines for PID treatment are available from the Centers for Disease Control (CDC), Atlanta, Georgia. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a1dfdfab-49d3-466d-8f58-bd32c01b4764"></a><a name="section-5.4.2"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span> has been associated with IUDs. Symptomatic women should have Skyla removed and should receive antibiotics. The significance of actinomyces-like organisms on Pap smear in an asymptomatic IUD user is unknown, and so this finding alone does not always require Skyla removal and treatment. When possible, confirm a Pap smear diagnosis with cultures.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0db1bb63-88b7-4276-a016-9a56b73806a9"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Pattern Alterations</h2>
<p class="First">Skyla can alter the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> pattern and result in spotting, irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, heavy <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span> and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. During the first 3–6 months of Skyla use, the number of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting days may be higher and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> patterns may be irregular. Thereafter, the number of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting days usually decreases but <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may remain irregular. <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> develops by the end of the first year of use in approximately 6% of Skyla users. In Skyla clinical trials, a total of 77 subjects out of 1,672 (4.6%) discontinued due to <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> complaints. Table 1 shows the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> patterns as documented in the Skyla clinical trials based on 90-day reference periods. Table 2 shows the number of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting days based on 28-day cycle equivalents. </p>
<table width="100%">
<caption><span>Table 1: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Patterns Reported with Skyla in Contraception Studies (by 90-day reference periods)</span></caption>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><span class="Sup">Defined as subjects with no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/spotting throughout the 90-day reference period</span></dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd><span class="Sup">Defined as subjects with 1 or 2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/spotting episodes in the 90-day reference period</span></dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd><span class="Sup">Defined as subjects with more than 5 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/spotting episodes in the 90-day reference period</span></dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd><span class="Sup">Defined as subjects with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/spotting episodes lasting more than 14 days in the 90-day reference period. Subjects with prolonged <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may also be included in one of the other categories (excluding <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>)</span></dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd><span class="Sup">Defined as subjects with 3 to 5 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/spotting episodes and less than 3 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/spotting-free intervals of 14 or more days</span></dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd><span class="Sup">The End of year 3 result for irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in particular is artificially inflated (46%) because removal was not timed to coincide with a complete 90-day reference period. The result from the preceding 90-day reference period (17%) provides a more relevant indication of the observed incidence near the end of the 3-year period.</span></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Skyla</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">First 90 days</span><br><span class="Bold">N=1,531</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Second 90 days</span><br><span class="Bold">N=1,475</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">End of year 1</span><br><span class="Bold">N=1,329</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">End of year 3</span><br><span class="Bold">N=903</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Infrequent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">20%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">22%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Frequent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">31%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Prolonged <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span><a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">59%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">17%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span><a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">42%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">28%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">23%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"> – <a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a></p></td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 2: Mean number of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and Spotting Days per 28-day Cycle Equivalent</span></caption>
<col width="15%">
<col width="12%">
<col width="5%">
<col width="12%">
<col width="5%">
<col width="12%">
<col width="5%">
<col width="12%">
<col width="5%">
<col width="12%">
<col width="5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">28-day Cycle Equivalent</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Cycle 1</span></p>
<p><span class="Bold">N=1,588</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Cycle 4</span></p>
<p><span class="Bold">N=1,535</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Cycle 7</span></p>
<p><span class="Bold">N=1,468</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Cycle 13</span></p>
<p><span class="Bold">N=1,345</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Cycle 39</span></p>
<p><span class="Bold">N=781</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Days on treatment</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">1–28</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">85–112</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">169–196</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">337–364</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">1065–1092</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">SD</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">SD</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">SD</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">SD</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">SD</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Number of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> days</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Number of spotting days</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.7</p></td>
</tr>
</tbody>
</table>
<p>Because irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/spotting is common during the first months of Skyla use, exclude endometrial pathology (<span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> or cancer) prior to the insertion of Skyla in women with persistent or uncharacteristic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If a significant change in <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> develops during prolonged use, take appropriate diagnostic measures to rule out endometrial pathology<span class="Italics">. </span>The possibility of pregnancy should be considered if menstruation does not occur within six weeks of the onset of a previous menstruation. Once pregnancy has been excluded, repeated pregnancy tests are generally not necessary in amenorrheic women unless indicated, for example, by other signs of pregnancy or by <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6fd0d21d-a70b-451d-81f3-643de5b7427d"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Perforation</h2>
<p class="First">Perforation (total or partial, including penetration/embedment of Skyla in the uterine wall or cervix) may occur most often during insertion, although the perforation may not be detected until sometime later. Perforation may reduce contraceptive efficacy and result in pregnancy. The incidence of perforation during clinical trials was &lt; 0.1%.</p>
<p>If perforation occurs, locate and remove Skyla. Surgery may be required. Delayed detection or removal of Skyla in case of perforation may result in migration outside the uterine cavity, <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesions</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforations</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span> and erosion of adjacent viscera. </p>
<p>Clinical trials with Skyla excluded breast-feeding women. An interim analysis from a large postmarketing safety study with other IUDs shows an increased risk of perforation in lactating women. The risk of perforation may be increased if Skyla is inserted when the uterus is fixed retroverted or not completely involuted during the postpartum period. Delay Skyla insertion a minimum of six weeks or until involution is complete following a delivery or a second trimester abortion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_918495c6-212c-432d-ae8b-8bd685d1f80b"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Expulsion</h2>
<p class="First">Partial or complete expulsion of Skyla may occur resulting in the loss of contraceptive protection. Expulsion may be associated with symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or it may be asymptomatic and go unnoticed. Skyla typically decreases menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> over time; therefore, an increase of menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may be indicative of an expulsion. The risk of expulsion may be increased when the uterus is not completely involuted. In clinical trials, a 3-year expulsion rate of 3.2% (54 out of 1665 subjects) was reported. </p>
<p>Delay Skyla insertion a minimum of six weeks or until uterine involution is complete following a delivery or a second trimester abortion. Remove a partially expelled Skyla. If expulsion has occurred, Skyla may be replaced within 7 days of a menstrual period after pregnancy has been ruled out. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7b8a0cbf-cc78-42c4-b92d-5bd527d02e1a"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian Cysts</span> </h2>
<p class="First">Because the contraceptive effect of Skyla is mainly due to its local effects within the uterus, ovulatory cycles with follicular rupture usually occur in women of fertile age using Skyla. During clinical trials, <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span> (reported as adverse reactions if they were abnormal, non-functional <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> and/or had a diameter &gt;3 cm on ultrasound examination) were reported in 13.2% of women using Skyla. Most of these <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> are asymptomatic, although some may be accompanied by <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span> or <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span>. In most cases the <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span> disappear spontaneously during two to three months observation. Persistent <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span> should be evaluated. <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">Surgical intervention</span> is not usually required. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_23144451-bab6-4c3e-8025-f7156ccf8098"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Breast Cancer </h2>
<p class="First">Women who currently have or have had breast cancer, or have a suspicion of breast cancer, should not use hormonal contraception because some breast cancers are hormone-sensitive <span class="Italics">[see Contraindications (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)]</span>. </p>
<p>Spontaneous reports of breast cancer have been received during postmarketing experience with another LNG IUS. Two observational studies have not provided evidence of an increased risk of breast cancer during the use of the other LNG IUS. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_99e9b4b9-dc8f-47cf-b086-be5334b37eed"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Clinical Considerations for Use and Removal</h2>
<p class="First">Use Skyla with caution after careful assessment if any of the following conditions exist, and consider removal of the system if any of them arise during use:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span> or use of anticoagulants</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span>, focal <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with asymmetrical visual loss or other symptoms indicating <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient cerebral ischemia</span></dd>
<dt>•</dt>
<dd>Exceptionally severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>•</dt>
<dd>Marked increase of blood pressure</dd>
<dt>•</dt>
<dd>Severe arterial disease such as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></dd>
</dl>
<p>In addition, consider removing Skyla if any of the following conditions arise during use <span class="Italics">[see Contraindications (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)]</span>:</p>
<dl>
<dt>•</dt>
<dd>Uterine or cervical malignancy </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span></dd>
<dt>•</dt>
<dd>If the threads are not visible or are significantly shortened they may have broken or retracted into the cervical canal or uterus. Consider the possibility that the system may have been displaced, (for example, expelled or perforated the uterus) <span class="Italics">[see Warnings and Precautions (<a href="#ID_6fd0d21d-a70b-451d-81f3-643de5b7427d">5.6</a>, <a href="#ID_918495c6-212c-432d-ae8b-8bd685d1f80b">5.7</a>)]</span>. Exclude pregnancy and verify the location of Skyla, for example, by sonography, X-ray, or by gentle exploration of the cervical canal with a suitable instrument. If Skyla is displaced, remove it. A new Skyla may be inserted at that time or during the next menses if it is certain that conception has not occurred. If Skyla is in place with no evidence of perforation, no intervention is indicated.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ab74cced-5f36-4d01-bf33-26311ecfc033"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Magnetic Resonance Imaging (MRI) Information</h2>
<p class="First">Non-clinical testing has demonstrated that Skyla is MR Conditional. Skyla can be safely scanned only under specific conditions:</p>
<dl>
<dt>•</dt>
<dd>Static magnetic field of 3 Tesla or less</dd>
<dt>•</dt>
<dd>Spatial gradient field of 36,000 Gauss/cm (T/m) or less</dd>
<dt>•</dt>
<dd>Maximum whole body averaged specific absorption rate (SAR) of <span class="Underline">4W/kg</span> in the First Level Controlled mode for 15 minutes of continuous scanning</dd>
</dl>
<p>In non-clinical testing, the Skyla produced a temperature rise of less than 1.8°C at a maximum whole body averaged specific absorption rate (SAR) of 2.9 W/kg, for 15 minutes of MR scanning at 3T using a transit/receive body coil. </p>
<p>MR Image quality may be compromised (that is, a small amount of artifact may occur) if the area of interest is in the exact same area or relatively close to the position of Skyla. Image artifact extended up to 5 mm from Skyla in a Gradient Echo pulse sequence.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_69bb649c-116a-4d94-b568-c37939a98900"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic Pregnancy</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_98be43d8-eb74-4bd7-992e-4c4fe58a1fc7">5.1</a>)]</span>
</dd>
<dt>•</dt>
<dd>Intrauterine Pregnancy <span class="Italics">[see Warnings and Precautions (<a href="#ID_f19ba4a2-53a7-4218-a9e4-88640f02eaa8">5.2</a>)]</span>
</dd>
<dt>•</dt>
<dd>Group A Streptococcal <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> (GAS) <span class="Italics">[see Warnings and Precautions (<a href="#ID_11851180-e0f7-4110-87a9-4a76a329d97d">5.3</a>)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">Pelvic Inflammatory Disease</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_23d1017a-874f-45d9-be1b-61c40e078409">5.4</a>)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Pattern Alterations <span class="Italics">[see Warnings and Precautions (<a href="#ID_0db1bb63-88b7-4276-a016-9a56b73806a9">5.5</a>)]</span>
</dd>
<dt>•</dt>
<dd>Perforation <span class="Italics">[see Warnings and Precautions (<a href="#ID_6fd0d21d-a70b-451d-81f3-643de5b7427d">5.6</a>)]</span>
</dd>
<dt>•</dt>
<dd>Expulsion <span class="Italics">[see Warnings and Precautions (<a href="#ID_918495c6-212c-432d-ae8b-8bd685d1f80b">5.7</a>)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian Cysts</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_7b8a0cbf-cc78-42c4-b92d-5bd527d02e1a">5.8</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ecfed523-f3a5-42e9-86c8-4f8ddad9cf3f"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. </p>
<p>The data described below reflect exposure to Skyla in 1,672 patients in two contraception studies, including 1,383 exposed for one year and 993 who completed the three year studies. The population was generally healthy, 18 to 40-year old females requesting contraception and predominately Caucasian (82.6%). The data cover more than 40,000 cycles of exposure. The frequencies of reported adverse drug reactions represent crude incidences. </p>
<p>Most common adverse reactions (occurring in ≥ 5% users) were increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (7.8%), <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span> (20.2%), abdominal/<span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span> (18.9%), <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>/<span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span> (15.0%), <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cyst</span> (13.2%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (12.4%), <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> (8.6%), <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (8.6%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5.5%). </p>
<p>In the contraception studies, 18% discontinued prematurely due to an adverse reaction. The most common adverse reactions leading to discontinuation (in &gt;1% of users) were <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> complaints (4.6%), <span class="product-label-link" type="condition" conceptid="4061671" conceptname="IUD expelled">device expulsion</span> (3.2%), <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>/<span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span> (2.9%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2.5%) <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>/<span class="product-label-link" type="condition" conceptid="4105918" conceptname="Uterine spasm">uterine spasms</span> (2.0%) and <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span> (1.8%).</p>
<p>Other common adverse reactions (occurring in ≥ 1% users) by System Organ Class (SOC): The frequencies of adverse reactions observed in clinical trials are summarized in Table 3 by SOC (presented as crude incidences). </p>
<table width="100%">
<caption><span>Table 3: Adverse reactions that occurred in at least 1% of Skyla users in clinical trials by SOC</span></caption>
<col width="33%">
<col width="37%">
<col width="29%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd><span class="Sup"><span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian cysts</span> were reported as AEs if they were abnormal, non-functional <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> and/or had a diameter &gt;3 cm on ultrasound examination</span></dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd><span class="Sup">Not all <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> alterations were captured as adverse reactions [see Warnings and Precautions (5.5)].</span></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">System Organ Class</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Incidence (%)<br>(N=1,672)</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">Vulvovaginitis</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>20.2</dd>
</dl></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian cyst</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>13.2</dd>
</dl></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhoea</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>8.6</dd>
</dl></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>Increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><span class="Sup"></span><a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>7.8</dd>
</dl></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>5.3/3.3</dd>
</dl></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">Genital discharge</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>4.2</dd>
</dl></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4061671" conceptname="IUD expelled">Device expulsion</span> (complete and partial)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>3.2</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>Upper genital tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>1.4</dd>
</dl></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>12.7/6.2</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>5.5</dd>
</dl></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">Skin and Subcutaneous<br>Tissue Disorders</p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>/<span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">Seborrhoea</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>13.6/1.4</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>1.2</dd>
</dl></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>12.4</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>2.3</dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Psychiatric Disorders</p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>/ <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">Depressed mood</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><dl>
<dt> </dt>
<dd>3.8/0.5</dd>
</dl></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b4dbb721-5e05-47b3-b789-e62fc27a440a"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of another LNG IUS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></dd>
<dt>•</dt>
<dd>Device breakage</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_efbaca52-20f3-4ef7-9053-d29b8bd8ca86"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No drug-drug interaction studies have been conducted with Skyla.</p>
<p>Drugs or herbal products that induce enzymes, including CYP3A4, that metabolize progestins may decrease the serum concentrations of progestins.</p>
<p>Some drugs or herbal products that may decrease the serum concentration of LNG include: </p>
<dl>
<dt>•</dt>
<dd>Barbiturates </dd>
<dt>•</dt>
<dd>Bosentan </dd>
<dt>•</dt>
<dd>Carbamazepine </dd>
<dt>•</dt>
<dd>Efavirenz</dd>
<dt>•</dt>
<dd>Felbamate </dd>
<dt>•</dt>
<dd>Griseofulvin</dd>
<dt>•</dt>
<dd>Nevirapine</dd>
<dt>•</dt>
<dd>Oxcarbazepine </dd>
<dt>•</dt>
<dd>Phenytoin </dd>
<dt>•</dt>
<dd>Rifabutin</dd>
<dt>•</dt>
<dd>Rifampin </dd>
<dt>•</dt>
<dd>St. John’s wort </dd>
<dt>•</dt>
<dd>Topiramate </dd>
</dl>
<p>Significant changes (increase or decrease) in the serum concentrations of the progestin have been noted in some cases of co-administration with HIV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors. CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels. </p>
<p>Consult the labeling of all concurrently used drugs to obtain further information about interactions with Skyla or the potential for enzyme alterations. </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_1f25a9eb-04f8-413e-8df8-fcff4008e64b"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_4cbeef67-9f29-4599-bf72-fd88a87eb224"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">The use of Skyla during an existing or suspected pregnancy is contraindicated. Many studies have found no harmful effects on fetal development associated with long-term use of contraceptive doses of oral progestins. The few studies of infant growth and development that have been conducted with progestin-only pills have not demonstrated significant adverse effects. <span class="Italics">[See Contraindications (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>) and Warnings and Precautions (<a href="#ID_98be43d8-eb74-4bd7-992e-4c4fe58a1fc7">5.1</a>, <a href="#ID_f19ba4a2-53a7-4218-a9e4-88640f02eaa8">5.2</a>).]</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_a22f3207-ca80-40ba-b9e1-f1e3c8a3242d"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">In general, no adverse effects of progestin-only contraceptives have been found on breastfeeding performance or on the health, growth, or development of the infant. Isolated postmarketing cases of decreased milk production have been reported. Small amounts of progestins were observed to pass into the breast milk of nursing mothers who used another LNG IUS, resulting in detectable steroid levels in infant serum. <span class="Italics">[See Warnings and Precautions (<a href="#ID_6fd0d21d-a70b-451d-81f3-643de5b7427d">5.6</a>).] </span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_84a25ae0-9473-4269-967f-2adefab7af76"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy of Skyla have been established in women of reproductive age. Efficacy is expected to be the same for postpubertal females under the age of 18 as for users 18 years and older. Use of this product before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is not indicated. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_af75f131-3b3a-486d-bf35-0151311c51f4"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Skyla has not been studied in women over age 65 and is not approved for use in this population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b3d1ef9f-8b2f-4177-a5b4-dd9071e0022c"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No studies were conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on the disposition of LNG released from Skyla <span class="Italics">[see Contraindications (<a href="#ID_41ab7112-df4d-468d-aae5-cbf9a0bf6be5">4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_381822e3-0980-4f3a-8d4d-29f3435ae0d2"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No studies were conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on the disposition of LNG released from Skyla.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_e6ef8532-f26b-4a4a-91fb-2904d6f94a74"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Skyla (LNG-releasing intrauterine system) contains 13.5 mg of LNG, a progestin, and is intended to provide an initial release rate of approximately14 mcg/day of LNG after 24 days.</p>
<p>Levonorgestrel USP, (-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one, the active ingredient in Skyla, has a molecular weight of 312.4, a molecular formula of C<span class="Sub">21</span>H<span class="Sub">28</span>O<span class="Sub">2</span>, and the following structural formula: </p>
<div class="Figure">
<a name="id714465238"></a><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-13.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_787edead-c232-40ef-8031-4bab5de304da"></a><a name="section-9.1"></a><p></p>
<h2>11.1 Skyla</h2>
<p class="First">Skyla consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The T-body has a loop at one end of the vertical stem and two horizontal arms at the other end. The reservoir consists of a whitish or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow cylinder, made of a mixture of LNG and silicone (polydimethylsiloxane), containing a total of 13.5 mg LNG. The reservoir is covered by a semi-opaque silicone membrane, composed of polydimethylsiloxane and colloidal silica. A ring composed of 99.95% pure silver is located at the top of the vertical stem close to the horizontal arms and is visible by ultrasound. The polyethylene of the T-body is compounded with barium sulfate, which makes it radiopaque. A monofilament brown polyethylene removal thread is attached to a loop at the end of the vertical stem of the T-body. The polyethylene of the removal thread contains iron oxide as a colorant (see Figure 10). </p>
<p>The components of Skyla, including its packaging, are not manufactured using natural rubber latex.</p>
<div class="Figure">
<a name="id-1839611724"></a><img alt="Skyla" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-11.jpg"><p class="MultiMediaCaption">Figure 10: Skyla</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7dfa3d64-06e9-4735-977b-b66370882c7f"></a><a name="section-9.2"></a><p></p>
<h2>11.2 Inserter </h2>
<p class="First">Skyla is packaged sterile within an inserter. The inserter (Figure 11), which is used for insertion of Skyla into the uterine cavity, consists of a symmetric two-sided body and slider that are integrated with flange, lock, pre-bent insertion tube and plunger. The outer diameter of the insertion tube is 3.8 mm. The vertical stem of Skyla is loaded in the insertion tube at the tip of the inserter. The arms are pre-aligned in the horizontal position. The removal threads are contained within the insertion tube and handle. Once Skyla has been placed, the inserter is discarded. </p>
<div class="Figure">
<a name="id30387594"></a><img alt="Inserter Diagram" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-12.jpg"><p class="MultiMediaCaption">Figure 11: Diagram of Inserter</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_9d058ef4-11af-42ee-add7-65635aef8142"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_1058da2e-c8a1-48f4-ac9d-a625d7df123c"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The local mechanism by which continuously released LNG enhances contraceptive effectiveness of Skyla has not been conclusively demonstrated. Studies of Skyla and similar LNG IUS prototypes have suggested several mechanisms that prevent pregnancy: thickening of cervical mucus preventing passage of sperm into the uterus, inhibition of sperm capacitation or survival, and alteration of the endometrium<span class="Bold">.</span></p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_a10ea836-f319-4e06-9075-e6a105beb9db"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Skyla has mainly local progestogenic effects in the uterine cavity. The high local levels of LNG2 lead to morphological changes including stromal pseudodecidualization, glandular <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, a leukocytic infiltration and a decrease in glandular and stromal mitoses. </p>
<p>In clinical trials with Skyla, ovulation was observed in the majority of a subset of subjects studied. Evidence of ovulation was seen in 34 out of 35 women in the first year, in 26 out of 27 women in the second year, and in all 27 women in the third year<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_4ee52ffb-a26f-4b67-8846-f164e9196e2e"></a><a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_75c20801-f64f-425c-8faf-36d7e4f188ff"></a><a name="section-10.3.1"></a><p></p>
<h3><span class="Bold">Absorption</span></h3>
<p class="First">Low doses of LNG are administered into the uterine cavity with the Skyla intrauterine delivery system. The <span class="Italics">in vivo</span> release rate is approximately 14 mcg/day after 24 days and is reduced to approximately 10 mcg/day after 60 days and then decreases progressively to approximately 5 mcg/day after three years. The average LNG <span class="Italics">in vivo</span> release rate is approximately 6 mcg/day over the period of three years. </p>
<p>In a subset of 7 subjects, maximum observed serum LNG concentration was 192 ± 105 pg/mL, reached after 2 days (median) of Skyla insertion. Thereafter, LNG serum concentration decreased after long-term use of 12, 24, and 36 months to concentrations of 77 ± 21 pg/mL, 62 ± 38 pg/mL, and 72 ± 29 pg/mL, respectively. A population pharmacokinetic evaluation based on a broader data base (&gt;1000 patients) showed similar concentration data of 168 ± 46 pg/mL at 7 days after placement. Thereafter, LNG serum concentrations decline slowly to a value 61 ± 19 pg/mL after 3 years.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_96cbf0c9-469b-4dc0-bd76-8776b130de63"></a><a name="section-10.3.2"></a><p></p>
<h3><span class="Bold">Distribution</span></h3>
<p class="First">The apparent volume of distribution of LNG is reported to be approximately 1.8 L/kg. Levonorgestrel is bound non-specifically to serum albumin and specifically to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG). Accordingly, changes in the concentration of SHBG in serum result in an increase (at higher SHBG concentration) or a decrease (at lower SHBG concentration) of the total LNG concentration in serum. In a subset of 7 subjects, the concentration of SHBG declined by a mean value of 18% within 2 weeks after insertion of Skyla and remains relatively stable over the 3 year period of use. Thereafter, plateau-like SHBG concentrations were observed. Less than 2 % of the circulating LNG is present as free steroid. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6587d1cb-ffa2-4a80-a6db-d9a1acf10ce1"></a><a name="section-10.3.3"></a><p></p>
<h3><span class="Bold">Metabolism</span></h3>
<p class="First">Following absorption, LNG is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in serum. Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydroLNG are also present in serum, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16β-hydroxylevonorgestrel. LNG and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for wide individual variations in LNG concentrations seen in individuals using LNG–containing contraceptive products. <span class="Italics">In vitro</span> studies have demonstrated that oxidative metabolism of LNG is catalyzed by CYP enzymes, especially CYP3A4. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bffb7060-cb41-4efb-853f-3e653be87cae"></a><a name="section-10.3.4"></a><p></p>
<h3><span class="Bold"> Excretion</span></h3>
<p class="First">About 45% of LNG and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates. The elimination half-life of LNG after parenteral administration is approximately 20 hours. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_86232cba-d246-4e35-b2db-6d53e05af981"></a><a name="section-10.3.5"></a><p></p>
<h3><span class="Bold">Specific Populations</span></h3>
<p class="First">Pediatric: Safety and efficacy of Skyla have been established in women of reproductive age. Use of this product before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is not indicated<span class="Italics">.</span></p>
<p>Geriatric: Skyla has not been studied in women over age 65 and is not currently approved for use in this population<span class="Italics">.</span></p>
<p>Race: No studies have evaluated the effect of race on pharmacokinetics of Skyla. </p>
<p><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: No studies were conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on the disposition of Skyla<span class="Italics">.</span></p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: No formal studies were conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on the disposition of Skyla. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_16107eec-acd4-4add-841f-413836a380c5"></a><a name="section-10.3.6"></a><p></p>
<h3><span class="Bold">Drug-Drug Interactions</span></h3>
<p class="First">No drug-drug interaction studies were conducted with Skyla <span class="Italics">[see Drug Interactions (<a href="#ID_efbaca52-20f3-4ef7-9053-d29b8bd8ca86">7</a>)]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_b3f82d21-b8f4-4bd8-bdaa-f48ccf65b504"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_19570f36-5d59-4469-821f-e8b3caf5fd2c"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">[See Warnings and Precautions (<a href="#ID_23144451-bab6-4c3e-8025-f7156ccf8098">5.9</a>).]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_3e443efa-2c74-404e-b347-e36f52a8243f"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4315f05a-8757-4d10-bc08-9467aed94433"></a><a name="section-12.1"></a><p></p>
<h2>14.1 Clinical Trials on Contraception</h2>
<p class="First">The contraceptive efficacy of Skyla was demonstrated in a clinical trial that enrolled generally healthy women aged 18–35, 1,432 of whom received Skyla. The Skyla arm included 38.8 % (556) nulliparous women. The trial was a multicenter, multi-national, randomized open label study conducted in 11 countries in Europe, Latin America, the US and Canada. Women less than six weeks postpartum, with a history of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>, with clinically significant <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span> or with HIV or otherwise at high risk for sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were excluded. For Skyla-treated women, 540 (37.7%) were treated at US sites and 892 (62.3%) were at non-US sites. The racial demographic of enrolled women who received Skyla was: Caucasian (79.7%), Hispanic (11.5%), Black (5.2%), Asian (0.8%), and Other (2.7%). The weight range for treated women was 38 to 155 kg (mean weight: 68.7 kg) and mean BMI was 25.3 kg/m<span class="Sup">2</span> (range 16–55 kg/m<span class="Sup">2</span>). Of Skyla-treated women, 21.9% discontinued the study treatment due to an adverse event, 4.4% were lost to follow up, 1.8% withdrew their consent, 13.0% discontinued due to other reason, 1.1% discontinued due to protocol deviation, and 0.6% discontinued due to pregnancy. </p>
<p>The pregnancy rate calculated as the Pearl Index (PI) in women aged 18–35 years was the primary efficacy endpoint used to assess contraceptive reliability. The PI was calculated based on 28-day equivalent exposure cycles; evaluable cycles excluded those in which back-up contraception was used unless a pregnancy occurred in that cycle. Skyla-treated women provided 15,763 evaluable 28-day cycle equivalents in the first year and 39,368 evaluable cycles over the three year treatment period. The PI estimate for the first year of use based on the 5 pregnancies that occurred after the onset of treatment and within 7 days after Skyla removal or expulsion was 0.41 with a 95% upper confidence limit of 0.96. The cumulative 3-year pregnancy rate, based on 10 pregnancies, estimated by the Kaplan-Meier method was 0.9 per 100 women or 0.9%, with a 95% upper confidence limit of 1.7%.</p>
<p>About 77% of women wishing to become pregnant conceived within 12 months after removal of Skyla.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_d993f59e-104b-469e-acc3-90e089f7a454"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First"><span class="Sup">1</span>Farley T M M, Rosenberg M J, Rowe P J, Chen J, Meirik O. Intrauterine devices and <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span>: an international perspective. Lancet 1992; 339:785-788.</p>
<p><span class="Sup">2</span>Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of LNG in women using a LNG-releasing IUD. Clinical Endocrinol 1982; 17:529-536.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_934e136d-ba3a-4dec-be32-5dd537c2d548"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<dl>
<dt> </dt>
<dd>Skyla (levonorgestrel-releasing intrauterine system), containing a total of 13.5 mg LNG, is available in a carton of one sterile unit. 	NDC# 50419-422-01 </dd>
</dl>
<p class="First">Skyla is supplied sterile. Skyla is sterilized with ethylene oxide. Do not resterilize. For single use only. Do not use if the inner package is damaged or open. Insert before the end of the month shown on the label.</p>
<p>Store at 25°C (77°F); with excursions permitted between 15–30°C (59–86°F) [see USP Controlled Room Temperature]. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_23724a84-1dde-4aa0-b581-25b75bc765f2"></a><a name="section-15"></a><p></p>
<h1> 17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Patient Information)</p>
<dl>
<dt>•</dt>
<dd>Counsel the patient that this product does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> (STDs).</dd>
<dt>•</dt>
<dd>Counsel the patient on the benefits, risks, and side effects of Skyla prior to insertion. Provide the Patient Information Booklet and give her the opportunity to read the information and discuss fully any questions she may have concerning Skyla as well as other methods of contraception. Advise the patient that the Full Prescribing Information is available to her upon request. </dd>
<dt>•</dt>
<dd>Inform the patient about the risks of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>, including the loss of fertility. Teach her to recognize and report to her healthcare provider promptly any symptoms of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>.</dd>
<dt>•</dt>
<dd>Inform the patient about the possibility of PID and that PID can cause tubal damage leading to <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> or <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, or infrequently can necessitate hysterectomy, or cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Teach patients to recognize and report to their physician promptly any symptoms of <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span>. These symptoms include development of <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorders</span> (prolonged or heavy <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>), unusual <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, abdominal or <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. </dd>
<dt>•</dt>
<dd>Counsel the patient that irregular or prolonged <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting, and/or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> may occur during the first few weeks after insertion. If her symptoms continue or are severe she should report them to her healthcare provider. </dd>
<dt>•</dt>
<dd>Counsel the patient on how she can check that the threads still protrude from the cervix and caution her not to pull on the threads and displace Skyla. Inform her that there is no contraceptive protection if Skyla is displaced or expelled. <span class="Italics">[See Warnings and Precautions (<a href="#ID_6fd0d21d-a70b-451d-81f3-643de5b7427d">5.6</a>, <a href="#ID_918495c6-212c-432d-ae8b-8bd685d1f80b">5.7</a>).]</span>
</dd>
<dt>•</dt>
<dd>Instruct the patient to contact her healthcare provider if she experiences any of the following: </dd>
<dt>•</dt>
<dd>A <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></dd>
<dt>•</dt>
<dd>Very severe or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span></dd>
<dt>•</dt>
<dd>Unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
<dt>•</dt>
<dd>Yellowing of the skin or whites of the eyes, as these may be signs of serious liver problems </dd>
<dt>•</dt>
<dd>Pregnancy or suspected pregnancy</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic pain</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> during sex</dd>
<dt>•</dt>
<dd>HIV positive seroconversion in herself or her partner</dd>
<dt>•</dt>
<dd>Possible exposure to sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (STIs)</dd>
<dt>•</dt>
<dd>Unusual <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> or genital sores</dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that lasts a long time, or if she misses a menstrual period</dd>
<dt>•</dt>
<dd>Inability to feel Skyla's threads</dd>
<dt>•</dt>
<dd>Inform the patient that Skyla can be safely scanned with MRI only under specific conditions <span class="Italics">[see Warnings and Precautions (<a href="#ID_ab74cced-5f36-4d01-bf33-26311ecfc033">5.11</a>)]</span>. Instruct patients who will have an MRI to tell their doctor that they have Skyla. This information is included on the Follow-Up Reminder Card.</dd>
<dt>•</dt>
<dd>Complete the Follow-up Reminder Card and give to the patient.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_5b9f3384-1bb9-413a-9ee7-2ace9e279414"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling </span></p>
<p><span class="Bold">Patient Information</span></p>
<p><span class="Bold">Skyla (sky-lah)</span></p>
<p>(levonorgestrel-releasing intrauterine system)</p>
<p><span class="Bold">Skyla does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (STIs).</span></p>
<p>Read this Patient Information carefully before you decide if Skyla is right for you. This information does not take the place of talking with your gynecologist or other healthcare provider who specializes in women’s health. If you have any questions about Skyla, ask your healthcare provider. You should also learn about other birth control methods to choose the one that is best for you.</p>
<p><span class="Bold">What is Skyla?</span></p>
<dl>
<dt>•</dt>
<dd>Skyla is a hormone-releasing system placed in your uterus by your healthcare provider to prevent pregnancy for up to 3 years.</dd>
<dt>•</dt>
<dd>Skyla can be removed by your healthcare provider at any time.</dd>
<dt>•</dt>
<dd>Skyla can be used whether or not you have had a child.</dd>
</dl>
<p>Skyla is a small, flexible plastic T-shaped system that slowly releases a progestin hormone called levonorgestrel that is often used in birth control pills. Because Skyla releases levonorgestrel into your uterus, only small amounts of the hormone enter your blood. Skyla does not contain estrogen.</p>
<p>Two thin threads are attached to the stem of Skyla. The threads are the only part of Skyla you can feel when Skyla is in your uterus; however, unlike a tampon string, the threads do not extend outside your body. </p>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top">
<a name="id1886513951"></a><img alt="Skyla is small" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-14.jpg">
</td>
<td align="center" valign="top">
<a name="id1712147068"></a><img alt="Skyla is flexible" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-15.jpg">
</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><p class="First">Skyla is small</p></td>
<td align="center" valign="top"><p class="First">and flexible</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">What if I need birth control for more than 3 years?</span></p>
<p>Skyla must be removed after 3 years. Your healthcare provider can place a new Skyla during the same office visit if you choose to continue using Skyla.</p>
<p><span class="Bold">What if I want to stop using Skyla?</span></p>
<p>Skyla is intended for long-term use but you can stop using Skyla at any time by asking your healthcare provider to remove it. You could become pregnant as soon as Skyla is removed, so you should use another method of birth control if you do not want to become pregnant. </p>
<p><span class="Bold">What if I change my mind about birth control and want to become pregnant in less than 3 years?</span></p>
<p>Your healthcare provider can remove Skyla at any time. You may become pregnant as soon as Skyla is removed. About 3 out of 4 women who want to become pregnant will become pregnant sometime in the first year after Skyla is removed.</p>
<p><span class="Bold">How does Skyla work?</span></p>
<p>Skyla may work in several ways including thickening cervical mucus, inhibiting sperm movement, reducing sperm survival, and thinning the lining of your uterus. It is not known exactly how these actions work together to prevent pregnancy.</p>
<div class="Figure">
<a name="id-1190444729"></a><img alt="Uterus" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-16.jpg">
</div>
<p><span class="Bold">How well does Skyla work for contraception?</span></p>
<p>The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.</p>
<p>Skyla, an intrauterine device (IUD), is in the box at the top of the chart.</p>
<div class="Figure">
<a name="id-1558698771"></a><img alt="Pregnancy Table" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=54653d3f-4ada-4273-ab83-224f83518ea9-17.jpg">
</div>
<p><span class="Bold">Who might use Skyla? </span></p>
<p>You might choose Skyla if you:</p>
<dl>
<dt>•</dt>
<dd>Want long-term birth control that provides a low chance of getting pregnant (less than 1 in 100)</dd>
<dt>•</dt>
<dd>Want birth control that works continuously for up to 3 years </dd>
<dt>•</dt>
<dd>Want birth control that is reversible</dd>
<dt>•</dt>
<dd>Want a birth control method that you do not need to take daily</dd>
<dt>•</dt>
<dd>Are willing to use a birth control method that is placed in the uterus </dd>
<dt>•</dt>
<dd>Want birth control that does not contain estrogen</dd>
</dl>
<p><span class="Bold">Who should not use Skyla?</span></p>
<p>Do not use Skyla if you:</p>
<dl>
<dt>•</dt>
<dd>Are or might be pregnant; Skyla cannot be used as an emergency contraceptive  </dd>
<dt>•</dt>
<dd>Have had a serious <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infection</span> called <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> (PID) unless you have had a <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> after the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> went away</dd>
<dt>•</dt>
<dd>Have an untreated <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infection</span> now</dd>
<dt>•</dt>
<dd>Have had a serious <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infection</span> in the past 3 months after a pregnancy</dd>
<dt>•</dt>
<dd>Can get <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> easily. For example, if you have:</dd>
<dt>o</dt>
<dd>Multiple sexual partners or your partner has multiple sexual partners</dd>
<dt>•</dt>
<dd>Problems with your immune system</dd>
<dt>•</dt>
<dd>Intravenous drug abuse</dd>
<dt>•</dt>
<dd>Have or suspect you might have cancer of the uterus or cervix</dd>
<dt>•</dt>
<dd>Have <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina that has not been explained</dd>
<dt>•</dt>
<dd>Have liver disease or <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span></dd>
<dt>•</dt>
<dd>Have breast cancer or any other cancer that is sensitive to progestin (a female hormone), now or in the past</dd>
<dt>•</dt>
<dd>Have an intrauterine device in your uterus already</dd>
<dt>•</dt>
<dd>Have a condition of the uterus that changes the shape of the uterine cavity, such as large fibroid tumors</dd>
<dt>•</dt>
<dd>Are allergic to levonorgestrel, silicone, polyethylene, silver, silica, barium sulfate or iron oxide</dd>
</dl>
<p><span class="Bold">Before having Skyla placed, tell your healthcare provider if you:</span></p>
<dl>
<dt>•</dt>
<dd>Have had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></dd>
<dt>•</dt>
<dd>Have had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></dd>
<dt>•</dt>
<dd>Were born with heart disease or have problems with your heart valves</dd>
<dt>•</dt>
<dd>Have problems with blood clotting or take medicine to reduce clotting</dd>
<dt>•</dt>
<dd>Have high blood pressure</dd>
<dt>•</dt>
<dd>Recently had a baby or if you are breastfeeding</dd>
<dt>•</dt>
<dd>Have severe <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span></dd>
</dl>
<p><span class="Bold">How is Skyla placed?</span></p>
<p>Skyla is placed by your healthcare provider during an in-office visit.</p>
<p>First, your healthcare provider will examine your pelvis to find the exact position of your uterus. Your healthcare provider will then clean your vagina and cervix with an antiseptic solution and slide a slim plastic tube containing Skyla into your uterus. Your healthcare provider will then remove the plastic tube, and leave Skyla in your uterus. Your healthcare provider will cut the threads to the right length. Placement takes only a few minutes.</p>
<p>You may experience <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> during and after placement. If your symptoms do not pass within 30 minutes after placement, Skyla may not have been placed correctly. Your healthcare provider will examine you to see if Skyla needs to be removed or replaced.</p>
<p><span class="Bold">Should I check that Skyla is in place?</span></p>
<p>Yes, you should check that Skyla is in proper position by feeling the removal threads. It is a good habit to do this once a month. Your healthcare provider should tell you how to check that Skyla is in place. First, wash your hands with soap and water. You can check by reaching up to the top of your vagina with clean fingers to feel the removal threads. Do not pull on the threads. If you feel more than just the threads or if you cannot feel the threads, Skyla may not be in the right position and may not prevent pregnancy. Use non-hormonal back-up birth control (such as condoms and spermicide) and ask your healthcare provider to check that Skyla is still in the right place.</p>
<p><span class="Bold">How soon after placement of Skyla should I return to my healthcare provider?</span></p>
<p>Call your healthcare provider if you have any questions or concerns (see “When should I call my healthcare provider?). Otherwise, you should return to your healthcare provider for a follow-up visit 4 to 6 weeks after Skyla is placed to make sure that Skyla is in the right position.</p>
<p><span class="Bold">Can I use tampons with Skyla?</span></p>
<p>Tampons may be used with Skyla.</p>
<p><span class="Bold">What if I become pregnant while using Skyla?</span></p>
<p>Call your healthcare provider right away if you think you are pregnant. If you get pregnant while using Skyla, you may have an <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>. This means that the pregnancy is not in the uterus. Unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> may be a sign of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic pregnancy</span> is a medical emergency that often requires surgery. <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic pregnancy</span> can cause internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>There are also risks if you get pregnant while using Skyla and the pregnancy is in the uterus. Severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>, <span class="product-label-link" type="condition" conceptid="4086393" conceptname="Premature delivery">premature delivery</span>, and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> can occur with pregnancies that continue with an intrauterine device (IUD). Because of this, your healthcare provider may try to remove Skyla, even though removing it may cause a <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>. If Skyla cannot be removed, talk with your healthcare provider about the benefits and risks of continuing the pregnancy.</p>
<p>If you continue your pregnancy, see your healthcare provider regularly. Call your healthcare provider right away if you get flu-like symptoms, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, cramping, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, or fluid leaking from your vagina. These may be signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>It is not known if Skyla can cause long-term effects on the fetus if it stays in place during a pregnancy.</p>
<p><span class="Bold">How will Skyla change my periods? </span></p>
<p>For the first 3 to 6 months, your period may become irregular and the number of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> days may increase. You may also have frequent spotting or light <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Some women have heavy <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during this time. After you have used Skyla for a while, the number of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting days is likely to lessen. There is a small chance that your periods will stop altogether.  </p>
<p><span class="Bold">Is it safe to breastfeed while using Skyla?</span></p>
<p>You may use Skyla when you are breastfeeding if more than six weeks have passed since you had your baby. If you are breastfeeding, Skyla is not likely to affect the quality or amount of your breast milk or the health of your nursing baby. However, isolated cases of decreased milk production have been reported among women using progestin-only birth control pills.</p>
<p><span class="Bold">Will Skyla interfere with sexual intercourse?</span></p>
<p>You and your partner should not feel Skyla during intercourse. Skyla is placed in the uterus, not in the vagina. Sometimes your partner feels the threads. If this occurs, talk with your healthcare provider.</p>
<p><span class="Bold">Can I have an MRI with Skyla in place?</span></p>
<p>Skyla can be safely scanned with MRI only under specific conditions. Before you have an MRI, tell your healthcare provider that you have Skyla.</p>
<p><span class="Bold">What are the possible side effects of Skyla?</span></p>
<p><span class="Bold">Skyla can cause serious side effects, including:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">Pelvic inflammatory disease</span> (PID).</span> Some IUD users get a serious <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infection</span> called <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span>. PID is usually sexually transmitted. You have a higher chance of getting PID if you or your partner have sex with other partners. PID can cause serious problems such as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> or <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span> that does not go away. PID is usually treated with antibiotics. More serious cases of PID may require surgery. A hysterectomy (removal of the uterus) is sometimes needed. In rare cases, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that start as PID can even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</dd>
<dt> </dt>
<dd>Tell your healthcare provider right away if you have any of these signs of PID: long-lasting or heavy <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, unusual <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, low abdominal (stomach area) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, painful sex, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</dd>
<dt> </dt>
<dd>
<span class="Bold">Life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span><span class="Italics">.</span></span> Life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> can occur within the first few days after Skyla is placed. Call your healthcare provider immediately if you develop severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> shortly after Skyla is placed.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span><span class="Italics">.</span></span> Life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> can occur within the first few days after Skyla is placed. Call your healthcare provider immediately if you develop severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> shortly after Skyla is placed.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Perforation.</span> Skyla may become attached to (embedded) or go through the wall of the uterus. This is called perforation. If this occurs, Skyla may no longer prevent pregnancy. If perforation occurs, Skyla may move outside the uterus and can cause internal <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or damage to other organs, and you may need surgery to have Skyla removed. The risk of perforation is increased in breastfeeding women.</dd>
</dl>
<p>Common side effects of Skyla include:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> during and after placement. If these symptoms do not stop 30 minutes after placement, Skyla may not have been placed correctly. Your healthcare provider will examine you to see if Skyla needs to be removed or replaced.</dd>
<dt>•</dt>
<dd>Expulsion. Skyla may come out by itself. This is called expulsion. Expulsion occurs in about 3 out of 100 women. You may become pregnant if Skyla comes out. If you think that Skyla has come out, use a backup birth control method like condoms and spermicide and call your healthcare provider.</dd>
<dt>•</dt>
<dd>Missed menstrual periods. About 1 out of 16 women stop having periods after 1 year of Skyla use. If you do not have a period for 6 weeks during Skyla use, call your healthcare provider. When Skyla is removed, your menstrual periods will come back.</dd>
<dt>•</dt>
<dd>Changes in <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. You may have <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting between menstrual periods, especially during the first 3-6 months. Sometimes the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is heavier than usual at first. However, the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> usually becomes lighter than usual and may be irregular. Call your healthcare provider if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> remains heavier than usual or increases after it has been light for a while.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">Cysts</span> on the ovary. About 14 out of 100 women using Skyla develop a <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> on the ovary. These <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> usually disappear on their own in a month or two. However, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> can cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and sometimes <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> will need surgery.</dd>
</dl>
<p>This is not a complete list of possible side effects with Skyla. For more information, ask your healthcare provider.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to the manufacturer at 1-888-842-2937, or FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch</span>.</p>
<p><span class="Bold">After Skyla has been placed, when should I call my healthcare provider?</span></p>
<p>Call your healthcare provider if you have any concerns about Skyla. Be sure to call if you:</p>
<dl>
<dt>•</dt>
<dd>Think you are pregnant</dd>
<dt>•</dt>
<dd>Have <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> during sex</dd>
<dt>•</dt>
<dd>Have unusual <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> or genital sores</dd>
<dt>•</dt>
<dd>Have unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, flu-like symptoms or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></dd>
<dt>•</dt>
<dd>Might be exposed to sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (STIs)</dd>
<dt>•</dt>
<dd>Cannot feel Skyla 's threads</dd>
<dt>•</dt>
<dd>Develop very severe or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span></dd>
<dt>•</dt>
<dd>Have yellowing of the skin or whites of the eyes. These may be signs of liver problems.</dd>
<dt>•</dt>
<dd>Have had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></dd>
<dt>•</dt>
<dd>Or your partner becomes HIV positive</dd>
<dt>•</dt>
<dd>Have severe <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that lasts a long time</dd>
</dl>
<p><span class="Bold">General advice about prescription medicines</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. This leaflet summarizes the most important information about Skyla. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider for information about Skyla that is written for health providers.</p>
<p>For more information, go to www.skyla-us.com or call 1-888-842-2937.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for:</p>
<p>Bayer HealthCare Pharmaceuticals Inc.<br>Wayne, NJ 07470</p>
<p>Manufactured in Finland</p>
<p>© 2013, Bayer HealthCare Pharmaceuticals Inc.<br>All rights reserved.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_0ad6ba41-4119-46b9-ad70-9f025129de7c"></a><a name="section-17"></a><p></p>
<p class="First">Skyla (levonorgestrel-releasing intrauterine system) Carton </p>
<p>NDC 50419-422-01 </p>
<p>1 Sterile Unit </p>
<p><span class="Bold">IMPORTANT: To be inserted in the uterus by or under the supervision of a licensed clinician. See physician insert for detailed instructions for use. </span></p>
<p><span class="Bold">Skyla </span></p>
<p><span class="Bold">(levonorgestrel-releasing intrauterine system) </span></p>
<p><span class="Bold">Rx only </span></p>
<p>— 13.5 mg levonorgestrel</p>
<p>— 1 sterile unit</p>
<p>— intrauterine use</p>
<div class="Figure">
<a name="id-265853756"></a><img alt="skyla trade carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f44ff35-e052-49cd-a1c2-0bfd87d49309&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SKYLA 		
					</strong><br><span class="contentTableReg">levonorgestrel intrauterine device</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50419-422</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAUTERINE</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVONORGESTREL</strong> (LEVONORGESTREL) </td>
<td class="formItem">LEVONORGESTREL</td>
<td class="formItem">13.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIMETHICONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BARIUM SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50419-422-01</td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50419-422-08</td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:50419-422-71</td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203159</td>
<td class="formItem">01/11/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bayer HealthCare Pharmaceuticals Inc.
							(005436809)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bayer Schering Pharma Oy</td>
<td class="formItem"></td>
<td class="formItem">369758383</td>
<td class="formItem">MANUFACTURE(50419-422)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1e206d2b-a0c5-4574-8015-2b698d5134ac</div>
<div>Set id: 9f44ff35-e052-49cd-a1c2-0bfd87d49309</div>
<div>Version: 7</div>
<div>Effective Time: 20130913</div>
</div>
</div> <div class="DistributorName">Bayer HealthCare Pharmaceuticals Inc.</div></p>
</body></html>
